newsfilter
← Latest News
GlobeNewswire·

Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates

- Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N=55) expected in the first half of